https://www.selleckchem.com/products/sc144.html
During the median follow up of 34 months (range, 8-67 months), 10 patients (59%, 10/17) developed new metastases. The 5-year disease-free survival rate was 32%. Four or fewer lung metastases (p=0.008) and metastases from colorectal carcinoma (p=0.02) were factors significantly associated with longer disease-free survival. One patient (6%, 1/17) died of tumor progression 29 months after initial treatment. The 5-year overall survival rate was 88%. The strategy of hybrid treatment involving surgery and radiofrequency ablation may offer good
Like
Comment
Share
